Johnson & Johnson (JNJ) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Johnson & Johnson (JNJ) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 -3.32%
Dec 28, 2025 24.10%
Sep 28, 2025 7.71%
Jun 29, 2025 8.84%
Mar 30, 2025 13.67%
Dec 31, 2023 -15.18%
Oct 1, 2023 40.73%
Jul 2, 2023 -15.54%
Apr 2, 2023 -37.31%
Jan 1, 2023 15.18%
Oct 2, 2022 -47.65%
Jul 3, 2022 -32.11%
Apr 3, 2022 -33.43%
Oct 3, 2021 -3.01%
Jul 4, 2021 9.45%
Apr 4, 2021 6.81%
Jan 3, 2021 -14.29%
Sep 27, 2020 1.14%
Jun 28, 2020 -4.29%
Mar 29, 2020 6.05%